The global REM sleep behavior disorder (RBD) market focuses on the diagnosis, management, and treatment of a sleep disorder where patients physically act out dreams during the REM (Rapid Eye Movement) phase of sleep. REM sleep is a critical stage marked by vivid dreaming and temporary muscle paralysis, which is absent in RBD, leading to movements that can cause injury. The disorder is primarily addressed through diagnostic tools such as video-polysomnography and AI-assisted monitoring, complemented by pharmacological treatments including clonazepam and melatonin.